Clinical Trials
17 trialsNCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
NCT00253318 2025-04-27
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT05065411 2024-02-26
VERU-024
Veru Inc.
Phase 3 Terminated
NCT00934895 2023-09-18
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT02269670 2022-04-05
Phase II Study of Everolimus Beyond Progression
Emory University
Phase 2 Terminated
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT02236572 2022-02-01
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
Yale University
Phase 2 Terminated
NCT02137837 2021-01-28
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
SWOG Cancer Research Network
Phase 3 Terminated
NCT01627067 2020-06-19
Exemestane-RAD001-Metformin
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01939418 2017-10-03
Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
National Cancer Center, Korea
Phase 1/2 Terminated
NCT02273752 2017-02-03
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Emory University
Phase 2 Terminated
NCT01773460 2016-02-10
Evelyn
GBG Forschungs GmbH
Phase 3 Terminated
NCT01272141 2014-09-22
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Emory University
Phase 2 Terminated
NCT00827567 2014-01-13
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
Milton S. Hershey Medical Center
Phase 2 Terminated
NCT00674414 2013-01-18
Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery
UNICANCER
Phase 2 Terminated
NCT00473005 2012-05-28
Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast
Stanford University
Phase 1 Terminated